News
In Novo Nordisk A/S’s home country of Denmark, the popularity of weight-loss drugs is fueling economic growth, but local ...
A once-weekly injection for weight loss known as a ‘GP-1 agonist’. It mimics a hormone in the gut that reduces our desire to eat and controls sugar in the blood. Developed originally for diabetes but ...
From legal pitfalls to temperature-sensitive drugs, here’s how to travel safely and legally with your medication ...
The rise of GLP-1 drugs is a reminder that we must move beyond the simple equation of thinness as health and value. These ...
It turns out that obesity may be much more complicated than we thought, with the condition potentially existing in up to 11 ...
17h
Zacks Investment Research on MSNCan Wegovy & Ozempic Drive Another Strong Quarter for Novo Nordisk?Novo Nordisk NVO generates most of its revenues from the sales of its blockbuster GLP-1 injections, Ozempic for type II ...
Explore more
On April 29, 2025, Hims & Hers and Novo Nordisk unveiled a landmark collaboration to bring Wegovy—Novo's blockbuster ...
23h
Onlymyhealth on MSNDon't Just Take Medication, Take Control: US Hospitals Recommend The MEAL Plan For Weight Loss SuccessUS hospitals recommend the MEAL plan for patients taking weight loss medications such as Wegovy and Ozempic Learn how this ...
A little weight gain during the menopause is normal, but when it happens to a generation who came of age in the skinny-chic Nineties and beach-body-ready Noughties, the judgement is real. It is ...
Novo Nordisk A/S (NYSE: NVO) is one of the high-margin pharma stocks to buy now. Berenberg has reaffirmed its Hold rating on ...
UnitedHealth Group's pharmacy benefits manager, OptumRx Inc., was hit with an Employee Retirement Income Security Act of 1974 ...
But taking them abroad isn’t always simple. From legal pitfalls to temperature-sensitive drugs, here’s how to travel safely and legally with your medication. Medicines that are legal in the UK can be ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results